NCT06873711View on ClinicalTrials.gov

The Associations of Microribonucleic Acid Gene Polymorphisms With the Risk of Ulcerative Colitis

CompletedOBSERVATIONAL

Enrollment

926

Participants

Timeline

Start Date

January 1, 2020

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions

Colitis, Ulcerative

Interventions

BIOLOGICAL

vedolizumab

Intravenous injection of VDZ (300mg/time) at weeks 0, 2, and 6, followed by intravenous injection of the same dose of VDZ every 8 weeks to maintain treatment.

Trial Locations (1)

Unknown

the Second Affiliated Hospital of Wenzhou Medical University, Wenzhou

All Listed Sponsors

lead

Second Affiliated Hospital of Wenzhou Medical University

OTHER

NCT06873711 - The Associations of Microribonucleic Acid Gene Polymorphisms With the Risk of Ulcerative Colitis | Biotech Hunter | Biotech Hunter